Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Maria E. Pasquale net worth and biography

Maria Pasquale Biography and Net Worth

EVP of Incyte

Maria E. Pasquale joined Incyte in April of 2018 as Executive Vice President and General Counsel with nearly 20 years of legal, compliance, and intellectual property experience in the pharmaceutical industry. Ms. Pasquale joined Incyte from Celgene Corporation, where for 17 years she held positions of increasing levels of responsibility including Chief Counsel; Senior Vice President, Legal and Deputy General Counsel and Assistant Corporate Secretary, where she was responsible for overseeing and managing Global Legal Departments including Intellectual Property, Regulatory, Litigation, Investigations and Transactional matters for Celgene’s Corporate Headquarters and its over 50 wholly owned subsidiaries; and, most recently, Maria served as Celgene’s Executive Vice President and Global Chief Compliance Officer, responsible for GxP and Healthcare Compliance globally. Prior to her tenure at Celgene, Ms. Pasquale spent a decade supporting pharmaceutical clients as a global patent and litigation attorney at Pennie & Edmonds LLP in New York (now part of Jones Day). Before her career in law, Ms. Pasquale was an Assistant Research Scientist at the Institute for Basic Research and the Cold Spring Harbor Laboratory, where she designed and implemented research projects in the areas of Alzheimer’s Disease and oncology, respectively. Ms. Pasquale holds a Juris Doctor Degree from Brooklyn Law School and a Bachelor of Science degree in biochemistry from the State University of New York at Stony Brook.

What is Maria E. Pasquale's net worth?: The estimated net worth of Maria E. Pasquale is at least $4.79 million as of January 30th, 2023. Ms. Pasquale owns 68,524 shares of Incyte stock worth more than $4,790,513 as of December 25th. This net worth estimate does not reflect any other assets that Ms. Pasquale may own. Learn More about Maria E. Pasquale's net worth.
How do I contact Maria E. Pasquale?: The corporate mailing address for Ms. Pasquale and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Maria E. Pasquale's contact information.
Has Maria E. Pasquale been buying or selling shares of Incyte?: Maria E. Pasquale has not been actively trading shares of Incyte within the last three months. Most recently, Maria E. Pasquale sold 60,024 shares of the business's stock in a transaction on Monday, January 30th. The shares were sold at an average price of $84.74, for a transaction totalling $5,086,433.76. Following the completion of the sale, the executive vice president now directly owns 68,524 shares of the company's stock, valued at $5,806,723.76. Learn More on Maria E. Pasquale's trading history.
Who are Incyte's active insiders?: Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (CEO & Chairman), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.
Are insiders buying or selling shares of Incyte?: During the last twelve months, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 65,984 shares worth more than $4,322,270.69. The most recent insider tranaction occured on December, 16th when insider Thomas Tray sold 650 shares worth more than $45,051.50. Insiders at Incyte own 17.6% of the company. Learn More about insider trades at Incyte.
Information on this page was last updated on 12/16/2024.

Maria E. Pasquale Insider Trading History at Incyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/30/2023	Sell	60,024	$84.74	$5,086,433.76	68,524
10/9/2020	Sell	1,423	$95.00	$135,185.00	29,754
9/10/2020	Sell	2,193	$90.83	$199,190.19	30,397
6/19/2020	Sell	1,423	$100.00	$142,300.00	25,084
4/16/2020	Sell	9,488	$95.00	$901,360.00	32,837
4/14/2020	Sell	17,827	$90.00	$1,604,430.00	23,864
4/6/2020	Sell	1,842	$85.00	$156,570.00	23,831

Maria E. Pasquale Buying and Selling Activity at Incyte

Incyte Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $69.91

$68.92

$70.10

50 Day Range

MA: $72.58

$65.07

$83.38

2 Week Range

Now: $69.91

$50.35

$83.95

Volume

395,905 shs

Average Volume

2,341,950 shs

Market Capitalization

$13.47 billion

P/E Ratio

499.39

Dividend Yield

N/A

Beta

0.69